MCID: BRN012
MIFTS: 59

Bronchiolitis Obliterans

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Bronchiolitis Obliterans

MalaCards integrated aliases for Bronchiolitis Obliterans:

Name: Bronchiolitis Obliterans 39 12 54 56 45 15 17 74
Obliterative Bronchiolitis 12 54 38
Bronchiolitis Fibrosa Obliterans 12 74
Bronchiolitis, Exudative 74
Bronchiolitis Exudativa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2799
KEGG 38 H01873
MeSH 45 D001989
NCIt 51 C62580
SNOMED-CT 69 31886003 40100001

Summaries for Bronchiolitis Obliterans

NIH Rare Diseases : 54 Bronchiolitis obliterans is an inflammatory condition that affects the lung's tiniest airways, the bronchioles. In affected people, the bronchioles may become damaged and inflamed leading to extensive scarring that blocks the airways. Signs and symptoms of the condition include a dry cough; shortness of breath; and/or fatigue and wheezing in the absence of a cold or asthma. Many different chemicals (such as nitrogen oxides, ammonia, welding fumes or food flavoring fumes) and respiratory infections can cause lung injury that leads to bronchiolitis obliterans. It can also be associated with rheumatoid arthritis and graft-versus-host disease following a lung or hematopoietic cell transplantation. While there is no way to reverse the disease, treatments are available that may stabilize or slow the progression. Another similarly named disease, bronchiolitis obliterans organizing pneumonia, is a completely different disease.

MalaCards based summary : Bronchiolitis Obliterans, also known as obliterative bronchiolitis, is related to cryptogenic organizing pneumonia and pneumonia. An important gene associated with Bronchiolitis Obliterans is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Montelukast and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include Lung, lung and bone, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A obstructive lung disease involving obstruction of the bronchioles due to inflammation and fibrosis which occurs as a complication of various lung conditions or physiological insults.

Wikipedia : 77 Bronchiolitis obliterans (BO), also known as obliterative bronchiolitis and popcorn lung, is a disease... more...

Related Diseases for Bronchiolitis Obliterans

Diseases related to Bronchiolitis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 404)
# Related Disease Score Top Affiliating Genes
1 cryptogenic organizing pneumonia 34.1 CXCL8 MMP9 TIMP1
2 pneumonia 32.0 CXCL8 IL10 IL6 TNF
3 bronchiolitis 31.9 CXCL8 IFNG IL10 IL17A IL6 TNF
4 hematopoietic stem cell transplantation 31.3 IFNG IL10 IL6 TNF
5 chronic graft versus host disease 31.0 IFNG IL10 TNF
6 respiratory failure 31.0 CXCL8 SCGB1A1 TNF
7 acute respiratory distress syndrome 30.8 CXCL8 IL6 TNF
8 hyperlucent lung 30.7 IFNG IL10
9 aspergillosis 30.6 IFNG IL10 TNF
10 graft-versus-host disease 30.5 GZMB IFNG IL10 IL6 TNF
11 arteries, anomalies of 30.4 IL6 MMP9 TNF
12 pulmonary edema 30.4 CXCL8 IL10 TNF
13 myasthenia gravis 30.4 IFNG IL10 TNF
14 cystitis 30.4 CXCL8 IL6 TNF
15 synovitis 30.4 CXCL8 IL6 TNF
16 rheumatic disease 30.4 IFNG IL10 TNF
17 pulmonary tuberculosis 30.4 IFNG IL10 TNF
18 cytomegalovirus infection 30.4 CXCL8 IL6 TNF
19 temporal arteritis 30.4 IFNG IL6 TNF
20 colitis 30.4 CXCL8 IFNG IL10 IL17A IL6 TNF
21 ulcerative colitis 30.4 CXCL8 IFNG IL10 IL17A IL6 TNF
22 spondylitis 30.3 IL17A IL6 TNF
23 pulmonary sarcoidosis 30.3 CXCR3 IFNG TNF
24 arthritis 30.3 CXCL8 IFNG IL10 IL17A IL6 MMP9
25 systemic lupus erythematosus 30.2 CXCR3 IFNG IL10 IL17A IL6 TNF
26 human immunodeficiency virus infectious disease 30.2 IFNG IL10 IL6 TNF
27 cutaneous lupus erythematosus 30.1 CXCR3 GZMB TNF
28 common variable immunodeficiency 30.1 IFNG IL10 IL6 TNF
29 chlamydia 30.1 CXCL8 IFNG IL10 IL6 TNF
30 adult respiratory distress syndrome 30.0 CXCL8 IL10 IL6 TNF
31 plasmodium vivax malaria 30.0 IFNG IL10 IL6 TNF
32 melioidosis 30.0 IFNG IL10 IL6 TNF
33 localized scleroderma 30.0 DEFB4A IL6 TNF
34 acquired immunodeficiency syndrome 29.9 IFNG IL10 IL6 TNF
35 castleman disease 29.9 IFNG IL10 IL6 PPL
36 rheumatoid arthritis 29.9 CXCL8 IFNG IL10 IL17A IL6 MMP9
37 acute graft versus host disease 29.9 GZMB IFNG IL10 TNF
38 extrinsic allergic alveolitis 29.8 CXCL8 CXCR3 IL10 IL6
39 mycoplasma pneumoniae pneumonia 29.8 IFNG IL10 IL17A IL6 TNF
40 inflammatory bowel disease 29.6 CXCL8 IFNG IL10 IL17A IL6 TNF
41 lung disease 29.5 CXCL8 CXCR3 IL10 IL17A IL6 MMP8
42 asthma 29.5 CXCL8 IFNG IL10 IL17A IL6 MMP9
43 pulmonary disease, chronic obstructive 29.3 CXCL8 CXCR3 IL17A IL6 MMP9 SCGB1A1
44 bone inflammation disease 29.2 CXCL8 IFNG IL10 IL17A IL6 TIMP1
45 pulmonary fibrosis, idiopathic 29.1 CXCL8 CXCR3 IFNG MMP9 PDGFB SCGB1A1
46 malaria 28.9 CXCL8 CXCR3 IFNG IL10 IL17A IL6
47 bronchiolitis obliterans with obstructive pulmonary disease 12.6
48 pemphigus 10.6
49 paraneoplastic pemphigus 10.6
50 buschke-ollendorff syndrome 10.6

Graphical network of the top 20 diseases related to Bronchiolitis Obliterans:



Diseases related to Bronchiolitis Obliterans

Symptoms & Phenotypes for Bronchiolitis Obliterans

MGI Mouse Phenotypes related to Bronchiolitis Obliterans:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.06 CXCR3 IFNG IL10 IL17A IL6 MMP8
2 hematopoietic system MP:0005397 10.02 CXCR3 IFNG IL10 IL17A IL6 MMP9
3 immune system MP:0005387 10 CXCR3 IFNG IL10 IL17A IL6 MMP8
4 neoplasm MP:0002006 9.81 CXCR3 IFNG IL10 IL6 MMP8 MMP9
5 renal/urinary system MP:0005367 9.5 CXCR3 IFNG IL17A IL6 MMP9 PDGFB
6 respiratory system MP:0005388 9.32 CXCR3 IFNG IL10 IL17A IL6 MMP9

Drugs & Therapeutics for Bronchiolitis Obliterans

Drugs for Bronchiolitis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4,Phase 2 158966-92-8 5281040
2
Azithromycin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83905-01-5 447043 55185
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 22916-47-8 4189
4
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
5
Mechlorethamine Approved, Investigational Phase 4,Phase 3 51-75-2 4033
6
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 441411 12560
7
Prednisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 53-03-2 5865
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 46835353 5284616 6436030
9
Azathioprine Approved Phase 4,Phase 2 446-86-6 2265
10
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 104987-11-3 6473866 445643 439492
11
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 70789204 6442177
12
Macitentan Approved Phase 4 441798-33-0
13
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
15
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
16 Hormones Phase 4,Phase 1,Phase 2,Not Applicable
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1,Phase 2,Not Applicable
18 Hormone Antagonists Phase 4,Phase 1,Phase 2,Not Applicable
19 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Autonomic Agents Phase 4,Phase 2,Not Applicable
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Gastrointestinal Agents Phase 4,Phase 2,Phase 1,Not Applicable
23 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
25 Antineoplastic Agents, Hormonal Phase 4,Phase 1,Phase 2,Not Applicable
26 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
28 glucocorticoids Phase 4,Phase 1,Phase 2,Not Applicable
29 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Calciferol Phase 4
32 Bone Density Conservation Agents Phase 4
33 Ergocalciferols Phase 4
34 Vitamin D2 Phase 4
35 Nutrients Phase 4
36 Olive Phase 4
37 Trace Elements Phase 4
38 Vitamins Phase 4
39 Micronutrients Phase 4
40 Calcium, Dietary Phase 4
41 Leukotriene Antagonists Phase 4,Phase 2
42 Respiratory System Agents Phase 4,Phase 2,Not Applicable
43 Anti-Asthmatic Agents Phase 4,Phase 2,Not Applicable
44 Cysteinyl-leukotriene Phase 4
45 Parasympatholytics Phase 4
46 Tocolytic Agents Phase 4,Not Applicable
47 Adrenergic beta-Agonists Phase 4,Phase 2,Not Applicable
48 Adrenergic Agonists Phase 4,Phase 2,Not Applicable
49 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2,Not Applicable
50 Cholinergic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 Vitamin D in Bronchiolitis Obliterans Syndrome Completed NCT01212406 Phase 4 Vitamin D
2 Montelukast in Bronchiolitis Obliterans Syndrome Completed NCT01211509 Phase 4 Montelukast
3 Bronchodilator Responsiveness in Obliterative Bronchiolitis Completed NCT01112241 Phase 4 albuterol plus tiotropium
4 Azithromycin in Bronchiolitis Obliterans Syndrome Completed NCT01009619 Phase 4 Azithromycin;Placebo
5 Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS) Completed NCT01469364 Phase 4 Aztreonam Lysine for Inhalation (AZLI)
6 Use of Erythromycin in Mustard-Induced Bronchiolitis Completed NCT00367419 Phase 4 Erythromycin
7 Comparison of Sirolimus and Azathioprine in Lung Transplantation Completed NCT00321906 Phase 4 azathioprine;sirolimus
8 Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation Completed NCT01109160 Phase 4 Azithromycin Dihydrate
9 Macitentan in the Treatment of Organ Rejection After Lung Transplantation Not yet recruiting NCT02893176 Phase 4 macitentan;placebo (for macitentan)
10 Tacrolimus Versus Cyclosporine for Immunosuppression After Lung Transplantation Completed NCT01429844 Phase 3 Tacrolimus;Cyclosporine
11 Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation Completed NCT00755781 Phase 3 Cyclosporine Inhalation Solution (CIS)
12 Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant Completed NCT00188825 Phase 3 basiliximab
13 Use of Clarithromycin in Mustard-Induced Bronchiolitis Completed NCT00381147 Phase 3 Clarithromycin
14 Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation Completed NCT00402532 Phase 3 Everolimus;Mycophenolatmofetil
15 Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients Completed NCT01404325 Phase 3 standard therapy;Everolimus
16 Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts Recruiting NCT02181257 Phase 3
17 A Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A Inhalation Solution in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Single Lung Transplant Recruiting NCT03657342 Phase 3 Liposomal Cyclosporine A
18 A Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A Inhalation Solution in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Double Lung Transplant Recruiting NCT03656926 Phase 3 Liposomal Cyclosporine A
19 European Trial of Pirfenidone in BOS, A European Multi-center Study Recruiting NCT02262299 Phase 2, Phase 3 Pirfenidone;Placebo
20 Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children Recruiting NCT02426112 Phase 3 Azithromycin;Placebo
21 Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting NCT01959100 Phase 3 Azithromycin;Placebo
22 Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 1-2 Not yet recruiting NCT03283007 Phase 3 Nintedanib;Placebo
23 Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) Terminated NCT01439958 Phase 3 Inhalation
24 L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients Terminated NCT01334892 Phase 2, Phase 3 Cyclosporine Inhalation Solution
25 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
26 CIS001 Extension Study of Cyclosporine Inhalation Solution Terminated NCT00938236 Phase 3 Cyclosporine Inhalation Solution (CIS)
27 A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT Unknown status NCT01639261 Phase 2 Interferon gamma 1b
28 MSC for Treatment of Interstitial Lung Disease After Allo-HSCT Unknown status NCT02543073 Phase 1, Phase 2 AZM;Glucocorticoid
29 Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Unknown status NCT00472225 Phase 2 Rituximab
30 Targeted Therapy of Bronchiolitis Obliterans Syndrome Completed NCT01307462 Phase 2 fluticasone propionate;montelukast sodium;azithromycin
31 Montelukast to Treat Bronchiolitis Obliterans Completed NCT00656058 Phase 2 Singulair (Montelukast Sodium)
32 Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation Completed NCT01560689 Phase 2 Budesonide/formoterol;Placebo
33 Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Completed NCT01287078 Phase 2 Cyclosporine Inhalation Solution
34 Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients Completed NCT01650545 Phase 1, Phase 2 Liposomal aerosol cyclosporine
35 Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT Completed NCT00624754 Phase 2 Formoterol/Budesonide;lactose
36 Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant Completed NCT00141726 Phase 2 Etanercept
37 Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation Completed NCT00029328 Phase 1, Phase 2 etanercept
38 Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment Completed NCT00079183 Phase 2 sirolimus
39 Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT Completed NCT02036970 Phase 2 Bardoxolone methyl;Placebo
40 Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation Recruiting NCT03805477 Phase 2 Nintedanib
41 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Recruiting NCT01273207 Phase 2 Cyclosporine Inhalation Solution (CIS)
42 Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) Recruiting NCT03674047 Phase 2 ruxolitinib
43 AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT02669251 Phase 1, Phase 2 AZD9668
44 Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction Recruiting NCT02709343 Phase 2 Bone-marrow derived MSCs;Placebo
45 Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure Recruiting NCT03500731 Phase 1, Phase 2 Rituximab;Alemtuzumab;Fludarabine;Thiotepa;G-CSF;Hydroxyurea
46 A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD Active, not recruiting NCT01163786 Phase 2 Bortezomib
47 Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation Active, not recruiting NCT02614872 Phase 2 GLASSIA® and Institution standard of care (SOC)
48 Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant Active, not recruiting NCT03330795 Phase 1, Phase 2
49 Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Enrolling by invitation NCT01852370 Phase 1, Phase 2
50 Hp129 Xenon Imaging and BOS in Lung Transplantation Not yet recruiting NCT03603899 Phase 1, Phase 2 Hp 129Xenon

Search NIH Clinical Center for Bronchiolitis Obliterans

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bronchiolitis Obliterans cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bronchiolitis Obliterans:
Mesenchymal stem cells for obliterative bronchiolitis
Embryonic/Adult Cultured Cells Related to Bronchiolitis Obliterans:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: bronchiolitis obliterans

Genetic Tests for Bronchiolitis Obliterans

Anatomical Context for Bronchiolitis Obliterans

MalaCards organs/tissues related to Bronchiolitis Obliterans:

42
Lung, Bone, Bone Marrow, Heart, T Cells, Breast, B Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchiolitis Obliterans:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Respiratory Bronchioles Cilliated Cells Affected by disease, potential therapeutic candidate

Publications for Bronchiolitis Obliterans

Articles related to Bronchiolitis Obliterans:

(show top 50) (show all 1508)
# Title Authors Year
1
Constrictive Bronchiolitis Obliterans in a Dog. ( 30653359 )
2019
2
Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome. ( 30663178 )
2019
3
Ruxolitinib is an effective steroid sparing agent in children with steroid refractory/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantation. ( 30683905 )
2019
4
The role of HIF-1α-VEGF pathway in bronchiolitis obliterans after lung transplantation. ( 30696477 )
2019
5
Bronchiolitis obliterans syndrome 'endotypes' in haematopoietic stem cell transplantation. ( 30730090 )
2019
6
Bronchiolitis Obliterans After Cefuroxime-Induced Stevens-Johnson Syndrome. ( 30737366 )
2019
7
Combination of pleuroparenchymal fibroelastosis with non-specific interstitial pneumonia and bronchiolitis obliterans as a complication of hematopoietic stem cell transplantation - Clues to a potential mechanism. ( 30792952 )
2019
8
Diagnosing and managing bronchiolitis obliterans in children. ( 30798629 )
2019
9
Precision medicine: integration of genetics and functional genomics in prediction of bronchiolitis obliterans after lung transplantation. ( 30883449 )
2019
10
EXERCISE CAPACITY IN CHILDREN AND ADOLESCENTS WITH POST-INFECTIOUS BRONCHIOLITIS OBLITERANS: A SYSTEMATIC REVIEW. ( 30892545 )
2019
11
Sporadic Obliterative Bronchiolitis: Case Series and Systematic Review of the Literature. ( 30899912 )
2019
12
Bronchiolitis Obliterans as long-term sequela of non-drug related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in children. ( 30908698 )
2019
13
Quantitative CT and pulmonary function in children with post-infectious bronchiolitis obliterans. ( 30934017 )
2019
14
An obligatory role for club cells in preventing obliterative bronchiolitis in lung transplants. ( 30990794 )
2019
15
Bronchiolitis obliterans syndrome as manifestation of lung GVHD: Not the only one. ( 31004374 )
2019
16
Bronchiolitis obliterans syndrome as manifestation of lung GVHD: Not the only one - Reply. ( 31004375 )
2019
17
Diagnostic value of ventilation/perfusion single-photon emission computed tomography/computed tomography for bronchiolitis obliterans syndrome in patients after lung transplantation. ( 31022070 )
2019
18
Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. ( 30038355 )
2019
19
Factors Associated With Mortality and Response to Extracorporeal Photopheresis in Lung Allograft Recipients With Bronchiolitis Obliterans Syndrome. ( 30130331 )
2019
20
Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis. ( 30391193 )
2019
21
HMGB1 blockade significantly improves luminal fibrous obliteration in a murine model of bronchiolitis obliterans syndrome. ( 30508580 )
2019
22
Association between chronic bacterial airway infection and prognosis of bronchiolitis obliterans syndrome after hematopoietic cell transplantation. ( 30608429 )
2019
23
Hemoptysis and Bronchiolitis Obliterans in Children with Recurrent Respiratory Papillomatosis: Adverse Reactions to Nebulized Cidofovir. ( 30611599 )
2019
24
Tamibarotene for the Treatment of Bronchiolitis Obliterans Associated With Chronic Graft-vs-Host Disease. ( 30616741 )
2019
25
Bronchiolitis obliterans in a transplant-waitlisted patient with hepatorenal polycystic disease. ( 29907421 )
2019
26
Bronchiolitis Obliterans without Joint Disease. A rare non-articular manifestation of Rheumatoid Arthritis ( 30547528 )
2018
27
Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy. ( 29998025 )
2018
28
Lung resident mesenchymal cells isolated from patients with the Bronchiolitis Obliterans Syndrome display a deregulated epigenetic profile. ( 30042393 )
2018
29
Comment on "Bronchiolitis Obliterans and Pulmonary Fibrosis after Sulfur Mustard Inhalation in Rats". ( 30067091 )
2018
30
Reply to: Comment on "Bronchiolitis Obliterans and Pulmonary Fibrosis after Sulfur Mustard Inhalation in Rats". ( 30067093 )
2018
31
Unicentric castleman disease complicated by paraneoplastic bronchiolitis obliterans and pemphigus. ( 30128272 )
2018
32
Lobe-wise assessment of lung volume and density distribution in lung transplant patients and value for early detection of bronchiolitis obliterans syndrome. ( 30150035 )
2018
33
Combined diffusing capacity for nitric oxide and carbon monoxide as predictor of bronchiolitis obliterans syndrome following lung transplantation. ( 30200966 )
2018
34
Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD. ( 30228128 )
2018
35
Clinical features of postinfectious bronchiolitis obliterans in children undergoing long-term nebulization treatment. ( 30269305 )
2018
36
The efficacy of extracorporeal photopheresis to arrest bronchiolitis obliterans in lung allograft recipients was compared between two automated photopheresis instruments. ( 30312482 )
2018
37
Case presentation: persistent adenovirus B3 infections associated with bronchiolitis obliterans treated with cidofovir in a child with mosaic tetrasomy 9p. ( 30348093 )
2018
38
Post-infectious bronchiolitis obliterans. ( 30548423 )
2018
39
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: the effect of NOD2/CARD15 mutations in a Tunisian population. ( 30552907 )
2018
40
C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans. ( 30568034 )
2018
41
Six-minute walk, lung clearance index, and QOL in bronchiolitis obliterans and cystic fibrosis. ( 30575341 )
2018
42
Bronchiolitis obliterans organizing pneumonia in Crohn's disease. ( 30578017 )
2018
43
Evolution of Functional Exercise Capacity in Lung Transplant Patients With and Without Bronchiolitis Obliterans Syndrome: A Longitudinal Case-Control Study. ( 30595421 )
2018
44
Obliterative Bronchiolitis as a Systemic Manifestation of Cutaneous Lupus Erythematosus. ( 30601199 )
2018
45
Post-infectious bronchiolitis obliterans in children: is general quality of life the right measure? ( 29438684 )
2018
46
Machine Learning Algorithms Utilizing Quantitative CT Features May Predict Eventual Onset of Bronchiolitis Obliterans Syndrome After Lung Transplantation. ( 29472146 )
2018
47
Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome After Lung Transplantation. ( 29557913 )
2018
48
High circulating CD4+CD25hiFOXP3+ T-cell sub-population early after lung transplantation is associated with development of bronchiolitis obliterans syndrome. ( 29571601 )
2018
49
Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial. ( 29624575 )
2018
50
Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. ( 29679771 )
2018

Variations for Bronchiolitis Obliterans

Expression for Bronchiolitis Obliterans

Search GEO for disease gene expression data for Bronchiolitis Obliterans.

Pathways for Bronchiolitis Obliterans

Pathways related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 CXCL8 DEFB4A IFNG IL10 IL17A IL6
2
Show member pathways
13.66 CXCL8 CXCR3 IFNG IL10 IL17A IL6
3
Show member pathways
13.53 CXCL8 IFNG IL10 IL17A IL6 PDGFB
4
Show member pathways
13.4 CXCL8 CXCR3 IL10 IL17A IL6 PDGFB
5
Show member pathways
13.35 CXCL8 IFNG IL10 IL17A IL6 MMP9
6
Show member pathways
13.3 CXCL8 CXCR3 IL10 IL17A IL6 PDGFB
7
Show member pathways
13.07 CXCL8 IFNG IL10 IL6 TNF
8
Show member pathways
12.89 CXCL8 GZMB IFNG IL10 IL17A IL6
9 12.84 CXCL8 IFNG IL6 MMP9 PDGFB
10
Show member pathways
12.61 IFNG IL10 IL17A IL6 TNF
11 12.58 GZMB IFNG IL10 IL17A TNF
12
Show member pathways
12.58 IFNG IL10 IL17A IL6 TNF
13
Show member pathways
12.55 IFNG IL10 IL17A IL6 PDGFB TIMP1
14
Show member pathways
12.39 IFNG IL10 IL6 PDGFB
15
Show member pathways
12.32 CXCL8 IFNG IL6 TNF
16 12.27 CXCL8 GZMB IL6 MMP9
17 12.25 IFNG IL10 IL6 TNF
18
Show member pathways
12.24 CXCL8 DEFB4A IFNG IL17A IL6 MMP9
19
Show member pathways
12.21 CXCL8 DEFB4A IFNG IL6 TNF
20 12.2 IFNG IL6 MMP9 TNF
21 12.2 CXCL8 IL10 IL6 TNF
22
Show member pathways
12.13 CXCL8 IFNG IL10 IL17A IL6 PDGFB
23 12.12 IFNG MMP9 PDGFB TNF
24
Show member pathways
12.09 IFNG IL10 IL17A IL6 TNF
25
Show member pathways
12.06 IFNG IL6 MMP9 TNF
26
Show member pathways
12.05 CXCL8 IFNG IL10 IL17A IL6 PDGFB
27 12.04 CXCL8 IFNG IL6 MMP9 TNF
28 12.02 IFNG IL10 IL6 TNF
29 11.95 IL6 MMP9 TNF
30
Show member pathways
11.94 MMP8 MMP9 TIMP1 TNF
31 11.93 CXCL8 IFNG IL6
32 11.92 CXCL8 IFNG IL10 IL6 TNF
33 11.91 IFNG IL6 TIMP1
34 11.9 CXCL8 IL6 TNF
35
Show member pathways
11.87 CXCL8 IL17A IL6
36 11.87 CXCL8 IFNG IL17A IL6 TNF
37 11.83 CXCL8 IFNG IL6
38 11.81 CXCL8 IFNG IL6
39 11.8 CXCL8 IL10 IL6 TNF
40 11.79 IFNG IL10 IL6 TNF
41
Show member pathways
11.77 CXCL8 IFNG TNF
42 11.7 CXCL8 IL6 MMP9
43 11.67 CXCL8 MMP9 TIMP1
44
Show member pathways
11.67 GZMB IFNG TNF
45
Show member pathways
11.65 CXCL8 IFNG IL6 MMP9 TNF
46 11.64 CXCR3 GZMB IFNG IL10 IL17A TNF
47 11.62 CXCL8 IFNG IL6
48 11.62 CXCL8 IL6 TNF
49 11.58 IFNG IL6 TNF
50 11.55 IL6 MMP9 TNF

GO Terms for Bronchiolitis Obliterans

Cellular components related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 CXCL8 DEFB4A IFNG IL10 IL17A IL6
2 extracellular space GO:0005615 9.4 CXCL8 DEFB4A IFNG IL10 IL17A IL6

Biological processes related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 IFNG IL6 MMP8 PDGFB TNF
2 negative regulation of gene expression GO:0010629 9.93 IFNG MMP8 PDGFB TNF
3 cellular response to lipopolysaccharide GO:0071222 9.85 CXCL8 IL10 IL6 TNF
4 inflammatory response GO:0006954 9.85 CXCL8 CXCR3 IL10 IL17A IL6 TNF
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.84 IL10 IL6 TNF
6 defense response to Gram-positive bacterium GO:0050830 9.83 DEFB4A IL6 TNF
7 wound healing GO:0042060 9.82 EVPL PPL TIMP1
8 cell chemotaxis GO:0060326 9.81 CXCR3 DEFB4A PDGFB
9 extracellular matrix disassembly GO:0022617 9.79 MMP8 MMP9 TIMP1
10 positive regulation of interleukin-6 production GO:0032755 9.78 IL6 MMP8 TNF
11 humoral immune response GO:0006959 9.77 IFNG IL6 TNF
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 IL6 PDGFB TNF
13 response to organic substance GO:0010033 9.76 IL10 SCGB1A1 TIMP1 TNF
14 immune response GO:0006955 9.76 CXCL8 CXCR3 DEFB4A IFNG IL10 IL17A
15 positive regulation of nitric oxide biosynthetic process GO:0045429 9.71 IFNG MMP8 TNF
16 response to glucocorticoid GO:0051384 9.71 IL10 IL6 SCGB1A1 TNF
17 positive regulation of glial cell proliferation GO:0060252 9.67 IL6 TNF
18 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.67 IFNG TNF
19 negative regulation of growth of symbiont in host GO:0044130 9.66 IL10 TNF
20 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 IL10 TNF
21 response to molecule of bacterial origin GO:0002237 9.64 CXCL8 IL10
22 negative regulation of lipid storage GO:0010888 9.63 IL6 TNF
23 endothelial cell apoptotic process GO:0072577 9.62 IL10 TNF
24 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.62 IL10 TIMP1
25 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.62 IL10 MMP9 PDGFB TNF
26 positive regulation of osteoclast differentiation GO:0045672 9.61 IFNG IL17A TNF
27 negative regulation of cytokine secretion involved in immune response GO:0002740 9.59 IL10 TNF
28 positive regulation of interleukin-23 production GO:0032747 9.57 IFNG IL17A
29 regulation of neuroinflammatory response GO:0150077 9.56 MMP8 MMP9
30 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 IFNG TNF
31 receptor biosynthetic process GO:0032800 9.51 IL10 TNF
32 cytokine-mediated signaling pathway GO:0019221 9.5 CXCL8 IL10 IL17A IL6 MMP9 TIMP1
33 regulation of microglial cell activation GO:1903978 9.49 MMP8 TNF
34 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 IFNG TNF
35 positive regulation of neuroinflammatory response GO:0150078 9.43 IL6 MMP8 TNF
36 regulation of signaling receptor activity GO:0010469 9.23 CXCL8 IFNG IL10 IL17A IL6 PDGFB

Molecular functions related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL10 IL6 PDGFB TIMP1
2 cytokine activity GO:0005125 9.17 CXCL8 IFNG IL10 IL17A IL6 TIMP1

Sources for Bronchiolitis Obliterans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....